29 results
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
known resistance pathways/mechanisms of current checkpoint inhibitors with established scientific rationales.
The Portage Approach
Our mission
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
scientific rationales.
The Portage Approach
Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
, and virus-like particles.
The Portage Approach
Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Nov 23
Current report (foreign)
4:01pm
rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles.
The Portage Approach
Our mission
424B3
PRTG
Portage Biotech Inc
7 Nov 23
Prospectus supplement
4:50pm
Approach
Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs
F-1
lxp9evd
31 Oct 23
Registration statement (foreign)
4:05pm
424B5
l8q3x1xk165hh5bf6aze
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.2
z3ud 4oyei
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.2
iafir2nm11fn2s2qi
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.2
znvqv5liovw8aaaga
29 Aug 22
Current report (foreign)
4:00pm
424B5
nc821
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
EX-99.2
yvzf4l9k1 x3rnr
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.1
g2bq7qf
15 Feb 22
Portage Biotech Announces New Appointments to its Management Team and Board of Directors
8:00am
6-K
EX-99.2
n1iikty fxoo
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.2
tahp 0831g8
30 Aug 21
Current report (foreign)
5:21pm
SUPPL
dyqtfg
24 Jun 21
Supplemental materials (foreign)
5:27pm
SUPPL
u8rww509j
23 Jun 21
Supplemental materials (foreign)
4:01pm